Product Description
Adenosine A1 Antagonist for Asthma and COPD (Sourced from: https://www.palobiofarma.com/pipeline-2/)
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Palobiofarma SL
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Respire | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-02-27 |
35% |
2021-001732-25 | P2 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2023-01-07 |
|
2017-003663-35 | P2 |
Active, not recruiting |
Asthma |
2019-02-14 |